How to select the optimal treatment for first line metastatic colorectal cancer

作     者：Alexander Stein Carsten Bokemeyer 

作者机构：Department of Oncology Haematology Stem Cell Transplantation with the Section Pneumology Hubertus Wald Tumor Centre University Cancer Centre Hamburg University Medical Centre Hamburg-Eppen-dorf 20246 Hamburg Germany 

出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)

年 卷 期：2014年第20卷第4期

页      面：899-907页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：Colorectal cancer Metastatic Induction chemotherapy Epidermal growth factor receptor 

摘      要：Choice of first line treatment for patients with metastatic colorectal cancer(mCRC)is based on tumour and patient related factors and molecular information for determination of individual treatment aim and thus treatment *** advances(e.g.,extended RAS testing)enable tailored patient assignment to the most beneficial treatment *** fluoropyrimidines,irinotecan and oxaliplatin,a broad variety of molecular targeting agents are currently available,e.g.,anti-angiogenic agents(bevacizumab)and epidermal growth factor receptor(EGFR)antibodies(cetuximab,panitumumab)for first line treatment of *** some combinations should be avoided(e.g.,oral or bolus fluoropyrimidines,oxaliplatin and EGFR antibodies),treatment options range from single agent to highly effective four-drug *** data comparing EGFR antibodies and bevacizumab,both with chemotherapy,seem to favour EGFR antibodies in RAS wildtype ***,choosing the most appropriate treatment approach for mCRC patients remains a complex issue,with numerous open questions.